SPHRY
Price
$1.45
Change
+$0.05 (+3.57%)
Updated
Sep 25 closing price
Capitalization
60.6M
45 days until earnings call
VACBF
Price
$0.20
Change
-$0.01 (-4.76%)
Updated
Sep 17 closing price
Capitalization
53.56M
Interact to see
Advertisement

SPHRY vs VACBF

Header iconSPHRY vs VACBF Comparison
Open Charts SPHRY vs VACBFBanner chart's image
Starpharma Holdings
Price$1.45
Change+$0.05 (+3.57%)
Volume$1.68K
Capitalization60.6M
NYKODE THERAPEUTICS AS
Price$0.20
Change-$0.01 (-4.76%)
Volume$10K
Capitalization53.56M
SPHRY vs VACBF Comparison Chart in %
Loading...
SPHRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VACBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SPHRY vs. VACBF commentary
Sep 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SPHRY is a StrongBuy and VACBF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 27, 2025
Stock price -- (SPHRY: $1.45 vs. VACBF: $0.20)
Brand notoriety: SPHRY and VACBF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SPHRY: 53% vs. VACBF: 149%
Market capitalization -- SPHRY: $60.6M vs. VACBF: $53.56M
SPHRY [@Biotechnology] is valued at $60.6M. VACBF’s [@Biotechnology] market capitalization is $53.56M. The market cap for tickers in the [@Biotechnology] industry ranges from $98.9B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SPHRY’s FA Score shows that 0 FA rating(s) are green whileVACBF’s FA Score has 1 green FA rating(s).

  • SPHRY’s FA Score: 0 green, 5 red.
  • VACBF’s FA Score: 1 green, 4 red.
According to our system of comparison, SPHRY is a better buy in the long-term than VACBF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SPHRY’s TA Score shows that 4 TA indicator(s) are bullish while VACBF’s TA Score has 0 bullish TA indicator(s).

  • SPHRY’s TA Score: 4 bullish, 3 bearish.
  • VACBF’s TA Score: 0 bullish, 3 bearish.
According to our system of comparison, SPHRY is a better buy in the short-term than VACBF.

Price Growth

SPHRY (@Biotechnology) experienced а +71.65% price change this week, while VACBF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.00%. For the same industry, the average monthly price growth was +9.18%, and the average quarterly price growth was +54.60%.

Reported Earning Dates

SPHRY is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+4.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SPHRY($60.6M) has a higher market cap than VACBF($53.6M). SPHRY YTD gains are higher at: 125.400 vs. VACBF (-16.944). SPHRY has higher annual earnings (EBITDA): -13.7M vs. VACBF (-21.96M). VACBF has higher revenues than SPHRY: VACBF (7.31M) vs SPHRY (2.98M).
SPHRYVACBFSPHRY / VACBF
Capitalization60.6M53.6M113%
EBITDA-13.7M-21.96M62%
Gain YTD125.400-16.944-740%
P/E RatioN/AN/A-
Revenue2.98M7.31M41%
Total CashN/A70M-
Total DebtN/A3.1M-
FUNDAMENTALS RATINGS
SPHRY: Fundamental Ratings
SPHRY
OUTLOOK RATING
1..100
88
VALUATION
overvalued / fair valued / undervalued
1..100
44
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
35
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
SPHRYVACBF
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
67%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
84%
N/A
Momentum
ODDS (%)
Bullish Trend 2 days ago
64%
Bearish Trend 2 days ago
45%
MACD
ODDS (%)
Bullish Trend 2 days ago
61%
Bearish Trend 2 days ago
38%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 2 days ago
13%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
56%
Bearish Trend 2 days ago
37%
Advances
ODDS (%)
Bullish Trend 2 days ago
63%
N/A
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
63%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
SPHRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VACBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
URLOF1.070.02
+1.90%
NameSilo Technologies Corp.
SUBCY20.960.34
+1.65%
Subsea 7 S.A.
PINXY12.48N/A
N/A
Peoples Insurance Company Group China
ICHIF2.69N/A
N/A
Ichigo Group Holdings Co Ltd.
MNXXF0.04N/A
-0.39%
Manganese X Energy Corp.

SPHRY and

Correlation & Price change

A.I.dvisor tells us that SPHRY and VACBF have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SPHRY and VACBF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPHRY
1D Price
Change %
SPHRY100%
N/A
VACBF - SPHRY
26%
Poorly correlated
N/A
SPHRF - SPHRY
26%
Poorly correlated
N/A
REVB - SPHRY
23%
Poorly correlated
+2.14%
ZBIO - SPHRY
22%
Poorly correlated
+7.89%
TTNP - SPHRY
22%
Poorly correlated
+2.98%
More

VACBF and

Correlation & Price change

A.I.dvisor tells us that VACBF and HYPD have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that VACBF and HYPD's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VACBF
1D Price
Change %
VACBF100%
N/A
HYPD - VACBF
27%
Poorly correlated
+13.12%
SPHRY - VACBF
26%
Poorly correlated
N/A
REVB - VACBF
26%
Poorly correlated
+2.14%
VTYX - VACBF
25%
Poorly correlated
+10.78%
AURA - VACBF
22%
Poorly correlated
+4.76%
More